Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05211570 · ClinicalTrials.gov registry record · Phase 1

AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

A Phase 1 study of Acute Myeloid Leukemia, in Relapse and Acute Myeloid Leukemia Refractory, sponsored by AB Science.

Recruiting
Registry status
Phase 1
Development phase
78
Enrollment target
10
Study locations

NCT05211570 is a Phase 1 study of Acute Myeloid Leukemia, in Relapse and Acute Myeloid Leukemia Refractory that is actively recruiting participants, run by AB Science. The registered enrollment target is 78 participants, above the 55-participant average among 16 other Acute Myeloid Leukemia, in Relapse trials with a reported enrollment target (42% higher). The trial reports 10 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05211570, a Phase 1 study of Acute Myeloid Leukemia, in Relapse and Acute Myeloid Leukemia Refractory, is actively recruiting participants, sponsored by AB Science.

RECRUITING
Registry status
Phase 1
Development phase
78 participants
Enrollment target
10
Study locations

Study Summary

The primary objective is to define the safety and tolerability of AB8939 in patients with AML by determining the dose-limiting toxicities, the maximum tolerated dose, and the recommended dose for dose expansion study.

Conditions Studied

Acute Myeloid Leukemia, in Relapse Acute Myeloid Leukemia Refractory Myelodysplastic Syndrome Acute Myeloid Leukemia

Interventions

  • DRUG Venetoclax
  • DRUG AB8939

Study Locations (10)

Other

  • Institut Paoli Calmettes - Marseille
  • National and Kapodistrian University of Athens NKUA · Department of Hematology and Bone marrow Transplantation Unit - Athens
  • General University Hospital of Alicantet (Hospital General Universitario Dr. Balmis de Alicante) - Alicante
  • Hospital San Pedro de Alcantara - Cáceres
  • Hospital Universitario 12 de Octubre - Madrid
  • Hospital Universitario Quirónsalud - Madrid
  • MD Anderson Cancer Center Madrid - Madrid
  • Clínica Universidad de Navarra - Pamplona
  • Virgen del Rocío University Hospital (Hospital Universitario Virgen del Rocío) - Seville

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 78 participants
Start Date 2022-06-01
Est. Completion 2026-12
Phase Phase 1

Sponsor

AB Science

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05211570

The ClinicalTrials.gov registry entry for NCT05211570 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 55-participant average among 16 other Acute Myeloid Leukemia, in Relapse trials with a reported enrollment target (42% higher). The listed sponsor is AB Science, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Acute Myeloid Leukemia, in Relapse appearing as the primary indexed condition, and to 2 interventions - of which Venetoclax is the first listed.

NCT05211570 reports 10 study locations spanning 2 distinct geographic areas - top geographies include Other, Texas.

Frequently Asked Questions

What is clinical trial NCT05211570 about?

NCT05211570 is a clinical study titled "AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia". The primary objective is to define the safety and tolerability of AB8939 in patients with AML by determining the dose-limiting toxicities, the maximum tolerated dose, and the recommended dose for dose expansion study.

What is the current status of trial NCT05211570?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2022-06-01. Estimated completion is 2026-12.

What conditions does trial NCT05211570 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, Myelodysplastic Syndrome Acute Myeloid Leukemia.

What interventions are being tested in trial NCT05211570?

The interventions under investigation include: Venetoclax (DRUG), AB8939 (DRUG).

Who is sponsoring clinical trial NCT05211570?

This trial is sponsored by AB Science, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05211570 being conducted?

This trial has 10 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia, in Relapse

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myeloid Leukemia, in Relapse

All registered trials for this condition

Acute Myeloid Leukemia Refractory

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.